Literature DB >> 3959903

Plasma triglycerides related decrease in high-density lipoprotein cholesterol and its association with myocardial infarction in heterozygous familial hypercholesterolemia.

S Moorjani, C Gagné, P J Lupien, D Brun.   

Abstract

Recent studies suggest that decreased levels of high-density lipoprotein (HDL) may contribute to the risk of premature occlusive atherosclerosis in familial hypercholesterolemia (FH). To investigate further, we have analyzed the concentration as well as distribution of HDL cholesterol in relation to plasma triglycerides and their influence on ischaemic heart disease in FH subjects. The study was carried out in 71 men with heterozygous FH and 46 matched controls. FH subjects were relatively young with a mean age of 38 +/- 11 years. Tendon xanthomatas were observed in 57% of the subjects, whereas ischemic heart disease was identified in 33%. Compared to normals, the mean value of HDL cholesterol is significantly reduced by 21% in FH heterozygotes (42 +/- 12 v 33 +/- 9 mg/dL, P less than 0.001). The decrease in HDL cholesterol is highly correlated to the levels of plasma triglycerides (r = -0.50, P less than 0.001) and VLDL cholesterol (r = -0.53, P less than 0.001). Moreover, HDL cholesterol decrease is not associated with elevated levels of LDL cholesterol (r = -0.20, NS), which is the primary characteristic feature of FH subjects. However, HDL cholesterol decrease is weakly related to total plasma cholesterol concentration (r = -0.24, P less than 0.05). The body weight is also contributory to the reduction of HDL cholesterol (r = -0.42, P less than 0.01), probably due to its strong positive correlation to plasma triglycerides (r = +0.54, P less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3959903     DOI: 10.1016/0026-0495(86)90146-0

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  8 in total

Review 1.  Role of lipid-lowering pharmacotherapy in children.

Authors:  S Tonstad
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

Review 2.  Borderline hypercholesterolaemia: when to introduce drugs.

Authors:  D Bhatnagar; P N Durrington
Journal:  Postgrad Med J       Date:  1989-08       Impact factor: 2.401

Review 3.  Clinical consequences of hyperlipidaemia.

Authors:  G R Thompson
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

Review 4.  Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia.

Authors:  P A Todd; A Ward
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

5.  The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation.

Authors:  M I Mackness; C Abbott; S Arrol; P N Durrington
Journal:  Biochem J       Date:  1993-09-15       Impact factor: 3.857

6.  Are gender differences in cardiovascular disease risk factors explained by the level of visceral adipose tissue?

Authors:  S Lemieux; J P Després; S Moorjani; A Nadeau; G Thériault; D Prud'homme; A Tremblay; C Bouchard; P J Lupien
Journal:  Diabetologia       Date:  1994-08       Impact factor: 10.122

7.  Dietary supplementation with fish gelatine modifies nutrient intake and leads to sex-dependent responses in TAG and C-reactive protein levels of insulin-resistant subjects.

Authors:  Eliane Picard-Deland; Charles Lavigne; Julie Marois; Julie Bisson; S John Weisnagel; André Marette; Bruce Holub; Eugene Chu; Jiri Frohlich; John S Hill; Hélène Jacques
Journal:  J Nutr Sci       Date:  2012-10-23

8.  Dietary Recommendations for Familial Hypercholesterolaemia: an Evidence-Free Zone.

Authors:  David M Diamond; Abdullah A Alabdulgader; Michel de Lorgeril; Zoe Harcombe; Malcolm Kendrick; Aseem Malhotra; Blair O'Neill; Uffe Ravnskov; Sherif Sultan; Jeff S Volek
Journal:  BMJ Evid Based Med       Date:  2020-07-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.